NEWS & EVENTS

MORE NEWS

Rivaroxaban receives draft NICE Guidance

National Institute for Health and Clinical Excellence issues draft guidance on Rivaroxaban the first once a day new oral anticoagulant for use in non-valvular atrial fibrillation

First new oral-anticoagulant in nearly 60 years, for stroke prevention in atrial fibrillation receives final guidance

The National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending the new oral anticoagulant, Pradaxa® (dabigatran etexilate) as an option for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (AF) and one or more risk factors. This decision means dabigatran must now be made available for use by the NHS and that patients have the right to receive it if clinicians deem it clinically appropriate.

New report unveils worrying truth that patients with AF are unaware of stroke risk - Leading charities call for change in the management of life-threatening condition

A new report launched by AntiCoagulation Europe (ACE) highlights that over half of UK patients diagnosed with AF are not aware of the condition’s life-threatening link to stroke. It also reveals that over half of these UK patients believe that their lives are more affected by their warfarin therapy to reduce risk of stroke than the condition itself.

Major report on Atrial Fibrillation launched by ACE.

A major source of information for patients and healthcare professionals on all aspects of AF, including urgent actions needed now to prevent untreated AF from causing a stroke epidemic.
Read the AF Report
Calculate your personal risk of stroke because of AF

Information for patients taking warfarin

Have you recently been prescribed warfarin and would like more information? For a beginners guide to warfarin please watch this short video. Video kindly created by Southampton University NHS Hospital Foundation Trust

SMC approves Rivaroxaban

On the 13th February 2012 The Scottish Medicines Consortium approved Rivaroxaban (Xarelto) for use in the prevention of stroke for patients with non-valvular atrial fibrillation and for the treatment of deep vein thrombosis and pulmonary embolism.

WELCOME TO ANTICOAGULATION EUROPE

INReview Magazine

INREVIEW MAGAZINE

We rely on donations and subscriptions so please consider joining or making a donation to enable us to coninue our work.

You can donate by clicking on to the link to right of this page. For easy ways to help us raise funds, at no cost to you, click on Give as You Live at the bottom of the page.


Order Your First Copy Free

Home insurance, protect what makes your house a home.
Read more.

Sign our E-petition to get the government to debate free prescriptions for long term users of anticoagulation therapy

https://submissions.epetitions.direct.gov.uk/petitions/29914

 

Anticoagulation in Practice Conference 17th & 18th May in Birmingham

Designed for Health Care Professionals and Patients 

To download programme and registration form click here

AntiCoagulation Europe, PO Box 405, Bromley, Kent BR2 9WP. Registered Charity: 1090250
Privacy | Terms & Conditions © Anticoagulation Europe 2011
Web design by Bright White Space